Psychiatric Multi-omics and Neuroimaging Project
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age13-35
Sponsormingjun Zhong
About this trial
This study focuses on the structure and function of the brain and gene expression in peripheral blood of patients with schizophrenia, to explore the interaction and influence between the three. Patients with mental disorders who have been recruited will take their medication regularly for 1 year and participate in baseline and follow-up assessments.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age: 13-35 years old(Patients with healthy siblings can be extended to 14-35 years of age)
Course of disease: <24 months
Priority is given to patients who have never taken medicine or duration of drug use < 2 weeks
No nuclear magnetic contraindications.
Disqualifiers
Family history of psychotic disorders, history of psychoactive substances abuse, alcohol dependence, or nicotine dependence
Have a major physical disease or infectious disease
History of coma and serious neurological disease 4.MRI contraindications.
Trial population
Patients from inpatient and outpatient the second Xiangya Hosptial of Central South University, Healthy controls from community, school and street recruitment
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
DrugPatients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
Treatment groups
1,899 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Group A: PMNP-Healthy Norms1 intervention
Group B: PMNP-Subclinical high-risk1 intervention
Group C: PMNP-Schizophrenia and Psychosis1 intervention
Group D: PMNP-MDD1 intervention
Group E: PMNP-ASD1 intervention
Group F: PMNP-BD1 intervention
Trial outcomes
Primary outcomes
1
cortical morphology
Data were obtained using magnetic resonance scans
Time frame
40 minutes2
target gene charaacteristics
10ml peripheral blood was extracted for gene analysis
Time frame
1 day3
scale scores
The score of each dimension and the total score were calculated according to the scale.The scale includes three dimensions: negative symptom, positive symptom and general psychopathology, and the score range of each dimension is different. The total score ranges from 30 to 210, with higher scores indicating worse results.
Time frame
90 minutes.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
mingjun Zhong
Lead sponsor
Second Xiangya Hospital of Central South University
Sponsor institution
Source ClinicalTrials.gov